Research Analysts Set Expectations for XFOR FY2024 Earnings

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Equities research analysts at HC Wainwright decreased their FY2024 EPS estimates for shares of X4 Pharmaceuticals in a research note issued on Thursday, November 14th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn ($0.66) per share for the year, down from their previous forecast of ($0.60). HC Wainwright has a “Buy” rating and a $1.50 price target on the stock. The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.67) per share. HC Wainwright also issued estimates for X4 Pharmaceuticals’ Q4 2024 earnings at ($0.17) EPS, Q2 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.41) EPS, FY2026 earnings at ($0.28) EPS, FY2027 earnings at ($0.14) EPS and FY2028 earnings at $0.04 EPS.

Separately, Stifel Nicolaus cut their target price on shares of X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating on the stock in a report on Thursday.

X4 Pharmaceuticals Stock Down 1.6 %

Shares of NASDAQ:XFOR opened at $0.40 on Monday. The company’s fifty day moving average price is $0.58 and its 200 day moving average price is $0.74. X4 Pharmaceuticals has a 12 month low of $0.26 and a 12 month high of $1.60. The company has a current ratio of 4.89, a quick ratio of 6.04 and a debt-to-equity ratio of 1.26.

Insider Activity

In related news, COO Mary Dibiase sold 67,695 shares of X4 Pharmaceuticals stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $0.57, for a total value of $38,586.15. Following the sale, the chief operating officer now directly owns 452,060 shares in the company, valued at $257,674.20. The trade was a 13.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Paula Ragan sold 239,436 shares of the firm’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $0.55, for a total value of $131,689.80. Following the completion of the sale, the chief executive officer now directly owns 1,057,713 shares of the company’s stock, valued at approximately $581,742.15. This trade represents a 18.46 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 580,800 shares of company stock valued at $321,447. Company insiders own 1.62% of the company’s stock.

Institutional Investors Weigh In On X4 Pharmaceuticals

Several institutional investors have recently modified their holdings of the company. GSA Capital Partners LLP acquired a new position in shares of X4 Pharmaceuticals during the 3rd quarter worth $340,000. K2 Principal Fund L.P. purchased a new stake in shares of X4 Pharmaceuticals in the second quarter valued at about $284,000. AQR Capital Management LLC increased its stake in shares of X4 Pharmaceuticals by 1,080.3% during the 2nd quarter. AQR Capital Management LLC now owns 424,042 shares of the company’s stock worth $246,000 after purchasing an additional 388,115 shares in the last quarter. State Street Corp grew its holdings in X4 Pharmaceuticals by 6.8% during the 3rd quarter. State Street Corp now owns 2,952,895 shares of the company’s stock valued at $1,976,000 after buying an additional 189,105 shares during the last quarter. Finally, Barclays PLC lifted its position in shares of X4 Pharmaceuticals by 196.0% in the third quarter. Barclays PLC now owns 277,682 shares of the company’s stock valued at $185,000 after acquiring an additional 183,861 shares in the last quarter. Hedge funds and other institutional investors own 72.03% of the company’s stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.